N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-2,3-norbornanedicarboximide | 103066-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-2,3-norbornanedicarboximide
• 英文别名: 2-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione；4-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione
• CAS: 103066-39-3
• 化学式: C₂₁H₂₉N₅O₂
• 分子量: 383.494
• InChiKey: CEIJFEGBUDEYSX-UHFFFAOYSA-N

物化性质

• 沸点：
  613.9±65.0 °C(Predicted)
• 密度：
  1.239±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  69.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  降莰烷-2,3-二甲酰亚胺 在 sodium hydride 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-2,3-norbornanedicarboximide
  参考文献：
  名称：

  Polycyclic aryl- and heteroarylpiperazinyl imides as 5-HT1A receptor ligands and potential anxiolytic agents: synthesis and structure-activity relationship studies

  摘要：

  A series of polycyclic aryl- and heteroarylpiperazinyl imides were prepared and tested in various receptor-binding and behavioral tests. Parameters measured included in vitro inhibition of D2 and 5-HT1A receptor binding, inhibition of apomorphine (APO) induced stereotyped and climbing behavior, and activity in blocking conditioned avoidance responding (CAR). Several compounds demonstrated moderate to high affinity for the 5-HT1A receptor binding site; compounds 27 and 36 containing the serotonin mimetic (o-methoxyphenyl)piperazinyl moiety and compounds 42 and 50 containing the 2-pyrimidinylpiperazinyl moiety displayed the highest affinity, being equal to that of the 5-HT1A agonist 8-OH-DPAT (Ki = 1-1.3 nM). In addition to affinity at 5-HT1A binding sites, many compounds were active in blocking CAR. Compound 34, 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]hexahydro-4,7-etheno-1H- cyclobut[f]isoindole-1,3(2H)-dione, demonstrated 3 times the activity of buspirone, blocking CAR in rats with an AB50 of 13 mg/kg. It also displayed high affinity for the 5-HT1A receptor (Ki = 16 nM), which is at least 20 times higher than its affinity for D2 (Ki = 345 nM) and 5-HT2 (Ki = 458 nM) receptors. Compound 34 was selected for further preclinical and pharmacokinetic evaluations for possible development as an anxiolytic agent. Structure-activity relationships within this series are discussed.

  DOI：

  10.1021/jm00402a023

文献信息

• Methods for treating attention deficit disorder
  申请人：Fabre Kramer Pharmaceutical, Inc.

  公开号：US20040002500A1

  公开（公告）日：2004-01-01

  The present invention relates to a method for treatment of attention deficit disorder by administering certain 5-HT 1A receptor agonists

  本发明涉及一种治疗注意力缺陷障碍的方法，通过给患者注射某些 5-HT 1A 受体激动剂
• Use of 5-HT1A receptor agonist compounds for inhibiting gastric acid secretion
  申请人：ELI LILLY AND COMPANY

  公开号：EP0455510B1

  公开（公告）日：1996-11-27
• ADATANSERIN AND METABOLITES THEREOF FOR TREATMENT OF ATTENTION DEFICIT DISORDER, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, AND OTHER DISORDERS
  申请人：KRAMER Stephen J.

  公开号：US20090281112A1

  公开（公告）日：2009-11-12

  The present invention relates to a method for alleviation, prevention, and treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, aggressive behavior, alcohol dependency, psychoses, and related conditions by administering adatanserin and/or metabolites of adatanserin. The present invention also relates to a method of weight loss by administering adatanserin and/or metabolites of adatanserin.
• 5 HT RECEPTOR MEDIATED NEUROGENESIS
  申请人：Barlow Carrolee

  公开号：US20100009983A1

  公开（公告）日：2010-01-14

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or activate the formation of new nerve cells.
• 5HT1A AGONISTS FOR TREATMENT OF HIGH CHOLESTEROL
  申请人：FABRE-KRAMER PHARMACEUTICALS, INC.

  公开号：US20130267533A1

  公开（公告）日：2013-10-10

  A method of treating and/or lowering elevated cholesterol by administering a therapeutically effective amount of at least one 5HT 1A receptor agonist to a subject in need thereof as either a short term or long term therapy. Also, a method of maintaining clinically acceptable cholesterol levels, or cholesterol levels below an elevated amount, by administering a therapeutically effective amount of at least one 5HT 1A receptor agonist to a subject in need thereof as either a short term or long term therapy.